ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Hyperviscous Diabetic Bone Marrow Niche Impairs BMSCs Osteogenesis via TRPV2-Mediated Cytoskeletal-Nuclear Mechanotransduction.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Reduced Arpc1b expression in astrocytes is associated with cytoskeletal remodeling, ALDOA redistribution, glycolysis, and neuroinflammation in a mouse model of bone cancer pain.Translational cancer research · 2026Article
- Artificial intelligence in orthopedic regenerative medicine: from design to clinical translational pathways.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The compromised regenerative capacity of diabetic bone defects remains a critical clinical challenge, with pathological alterations in the bone marrow microenvironment emerging as key contributors. While mechanical signals within the marrow niche critically regulate bone regeneration, how diabetic matrix abnormalities impair bone marrow-derived mesenchymal stem cells (BMSCs) function remains unclear. Herein, it is revealed that diabetes induces a characteristic hyperviscous state in bone marrow extracellular matrix (ECM). Through comparative mechanobiological analyses, it is demonstrated that diabetic BMSCs exhibit amplified mechanosensitivity to ECM viscosity via transient receptor potential vanilloid 2 (TRPV2) activation. This mechanotransduction cascade triggers calcium influx, which activates CaMKII and subsequently phosphorylates cofilin, thereby shifting the G-/F-actin equilibrium toward perinuclear F-actin disassembly. The cytoskeletal remodeling induces nuclear envelope deformation through regulation of Lamin A/C, driving spatial rearrangement of chromatin architecture. Mechanistically, these physical nuclear changes promote perinuclear heterochromatin accumulation and enhance H3K9me3 repressive histone modification, ultimately suppressing osteogenic transcriptional programs. Importantly, TRPV2 inhibition rescued both chromatin accessibility and osteogenic potential in diabetic BMSCs. This findings establish a novel mechano-pathological axis where diabetic ECM hyperviscosity propagates mechanical signals from cytoskeleton to chromatin through TRPV2 activation, proposing mechanomodulation as a promising therapeutic strategy for diabetic osteopathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.